Polysaccharide of Ganoderma lucidum Ameliorates Cachectic Myopathy Induced by the Combination Cisplatin plus Docetaxel in Mice
Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Cachexia is a lethal muscle-wasting syndro...
Saved in:
| Published in | Microbiology spectrum Vol. 11; no. 3; p. e0313022 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
15.06.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients.
Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the
Ganoderma lucidum
polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes (
MuRF-1
and
Atrogin-1
) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of
Ruminococcaceae
and
Bacteroides
, but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia.
IMPORTANCE
Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus
Ganoderma lucidum
. This study is the first to report that
G. lucidum
polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as
MuRF-1
and
Atrogin-1.
These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. |
|---|---|
| AbstractList | Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes (MuRF-1 and Atrogin-1) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of Ruminococcaceae and Bacteroides, but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. IMPORTANCE Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum. This study is the first to report that G. lucidum polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as MuRF-1 and Atrogin-1. These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes ( MuRF-1 and Atrogin-1 ) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of Ruminococcaceae and Bacteroides , but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. IMPORTANCE Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum . This study is the first to report that G. lucidum polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as MuRF-1 and Atrogin-1. These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes ( MuRF-1 and Atrogin-1 ) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of Ruminococcaceae and Bacteroides , but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. IMPORTANCE Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum . This study is the first to report that G. lucidum polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as MuRF-1 and Atrogin-1. These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes (MuRF-1 and Atrogin-1) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of Ruminococcaceae and Bacteroides, but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. IMPORTANCE Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum. This study is the first to report that G. lucidum polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as MuRF-1 and Atrogin-1. These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia.Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes (MuRF-1 and Atrogin-1) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of Ruminococcaceae and Bacteroides, but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. IMPORTANCE Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum. This study is the first to report that G. lucidum polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as MuRF-1 and Atrogin-1. These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. ABSTRACT Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes (MuRF-1 and Atrogin-1) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of Ruminococcaceae and Bacteroides, but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. IMPORTANCE Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum. This study is the first to report that G. lucidum polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as MuRF-1 and Atrogin-1. These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and intestinal microbiota, but there is presently no effective treatment for cachexia. Whether the Ganoderma lucidum polysaccharide Liz-H exerts protective effects on cachexia and gut microbiota dysbiosis induced by the combination cisplatin plus docetaxel (cisplatin + docetaxel) was investigated. C57BL/6J mice were intraperitoneally injected with cisplatin + docetaxel, with or without oral administration of Liz-H. Body weight, food consumption, complete blood count, blood biochemistry, and muscle atrophy were measured. Next-generation sequencing was also performed to investigate changes to gut microbial ecology. Liz-H administration alleviated the cisplatin + docetaxel-induced weight loss, muscle atrophy, and neutropenia. Furthermore, upregulation of muscle protein degradation-related genes ( and ) and decline of myogenic factors (MyoD and myogenin) after treatment of cisplatin and docetaxel were prevented by Liz-H. Cisplatin and docetaxel treatment resulted in reducing comparative abundances of and , but Liz-H treatment restored these to normal levels. This study indicates that Liz-H is a good chemoprotective reagent for cisplatin + docetaxel-induced cachexia. Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients with advanced cancer have cachexia, and cachexia is the cause of death in 30% of cancer patients. Nutritional supplementation has not been shown to reverse cachexia progression. Thus, developing strategies to prevent and/or reverse cachexia is urgent. Polysaccharide is a major biologically active compound in the fungus Ganoderma lucidum. This study is the first to report that polysaccharides could alleviate chemotherapy-induced cachexia via reducing expression of genes that are known to drive muscle wasting, such as and These results suggest that Liz-H is an effective treatment for cisplatin + docetaxel-induced cachexia. |
| Author | Jan, Ming-Shiou Wu, Sung-Yu Hsin, I-Lun Ko, Jiunn-Liang Ou, Chu-Chyn Kang, Yu-Ting Lee, Meng-Lin |
| Author_xml | – sequence: 1 givenname: Sung-Yu surname: Wu fullname: Wu, Sung-Yu organization: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Department of Ophthalmology, Chung Shan Medical University Hospital, Taichung, Taiwan – sequence: 2 givenname: Chu-Chyn surname: Ou fullname: Ou, Chu-Chyn organization: Department of Nutrition, Chung Shan Medical University, Taichung, Taiwan – sequence: 3 givenname: Meng-Lin surname: Lee fullname: Lee, Meng-Lin organization: Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan – sequence: 4 givenname: I-Lun surname: Hsin fullname: Hsin, I-Lun organization: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan – sequence: 5 givenname: Yu-Ting surname: Kang fullname: Kang, Yu-Ting organization: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan – sequence: 6 givenname: Ming-Shiou surname: Jan fullname: Jan, Ming-Shiou organization: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan, Department of Health Industry Technology Management, Chung Shan Medical University, Taichung, Taiwan – sequence: 7 givenname: Jiunn-Liang orcidid: 0000-0001-6855-9239 surname: Ko fullname: Ko, Jiunn-Liang organization: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Department of Medical Oncology and Chest Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37212664$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ksFuEzEQhleoiJbSB-CCfOSSYHt37eSEqgAlUis4wNmanZ1tHHntxd6tyIVnx00a1CLBySPPP9_89szL4sQHT0XxWvC5EHLxLg2EY5z6OS9FyWdSPivOpFD1jFdLffIoPi0uUtpyzoXgtazli-K01FJIpaqz4tfX4HYJEDcQbUssdOwKfGgp9sDchLadenbZk7MhwkiJrQA3ubFFdrMLA4ybHVv7dkJqWbNj44bYKvSN9TDa4NnKpsHl0LPBTYl9CEgj_CTH8s2NRXpVPO_AJbp4OM-L758-flt9nl1_uVqvLq9nUPN6nDU10pKqUjYLrFVH2MlOI6emrmApAUBJ3SmhSiVQt7ItK2yanBJlp-qKsDwv1gduG2Brhmh7iDsTwJr9RYi3BmJ-lCMjSuDEkcuyxkrK5UJDtehyf91mF1WdWe8PrGFqemqR_BjBPYE-zXi7Mbfhzggu1TIDMuHtAyGGHxOl0fQ2ITkHnsKUjFwIrbXi-l46P0gh9dJswxR9_qeMMvdLYI5LYPZLYKTMBW8eu_tj6zjyLNAHAcaQUqTOoB3308pmrfsvWvxVeYT_u-Y3fUXXrA |
| CitedBy_id | crossref_primary_10_1186_s12906_024_04445_x crossref_primary_10_3390_molecules28196816 crossref_primary_10_1080_0028825X_2024_2375996 crossref_primary_10_1016_j_ijbiomac_2025_140645 crossref_primary_10_1016_j_fbio_2025_105990 crossref_primary_10_3389_fmicb_2024_1362479 |
| Cites_doi | 10.1016/j.carbpol.2021.118231 10.1002/jcsm.12684 10.1371/journal.pone.0131009 10.1016/j.cmet.2012.06.011 10.1210/en.2013-1179 10.1016/j.phrs.2019.104448 10.1002/btpr.3027 10.18632/oncotarget.9779 10.1002/jcsm.12023 10.1016/S1470-2045(10)70218-7 10.1016/j.jff.2015.09.042 10.1016/j.clnu.2008.06.013 10.1016/j.beem.2021.101508 10.1111/bph.15693 10.1016/0026-0495(95)90040-3 10.1038/s41598-018-30569-5 10.1016/j.cell.2010.08.004 10.1016/j.bbrc.2018.09.105 10.1155/2014/168407 10.1189/jlb.0804481 10.1002/jcsm.12111 10.1186/s41702-019-0044-0 10.1200/JCO.2004.11.004 10.1016/j.carbpol.2020.117594 10.1016/j.jff.2018.05.041 10.29219/fnr.v63.1559 10.1371/journal.pone.0204895 10.4081/ejtm.2018.7590 10.1002/kjm2.12020 10.1016/j.ijbiomac.2021.12.034 10.1016/j.ijbiomac.2016.09.029 10.1371/journal.pone.0037971 10.1038/ncomms8489 10.1016/j.taap.2010.11.003 10.1016/j.ijbiomac.2019.11.047 10.3109/08923973.2013.791834 10.4081/ejtm.2018.7587 10.3389/fcimb.2019.00305 10.1016/j.etp.2009.11.003 10.1111/apt.13302 10.1016/j.cell.2016.05.041 10.1002/jcsm.12804 10.1002/jcp.29924 10.1111/apt.12878 10.1007/s00280-020-04060-w 10.3390/polym13244353 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Wu et al. Copyright © 2023 Wu et al. 2023 Wu et al. |
| Copyright_xml | – notice: Copyright © 2023 Wu et al. – notice: Copyright © 2023 Wu et al. 2023 Wu et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1128/spectrum.03130-22 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2165-0497 |
| Editor | Hung, Yuan Pin |
| Editor_xml | – sequence: 1 givenname: Yuan Pin surname: Hung fullname: Hung, Yuan Pin |
| ExternalDocumentID | oai_doaj_org_article_13a0e0c0235c422987a48fce97d5ce45 PMC10269453 03130-22 37212664 10_1128_spectrum_03130_22 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Ministry of Science and Technology, Taiwan (MOST) grantid: MOST 108-2320-B-040 -015 -MY3 – fundername: Ministry of Science and Technology, Taiwan (MOST) grantid: MOST 108-2320-B-040 -015 -MY3; MOST 111-2320-B-040 -018 -MY3 funderid: https://doi.org/10.13039/501100004663 – fundername: ; grantid: MOST 108-2320-B-040 -015 -MY3; MOST 111-2320-B-040 -018 -MY3 |
| GroupedDBID | 53G AAGFI AAUOK AAYXX ADBBV AGVNZ ALMA_UNASSIGNED_HOLDINGS CITATION EJD FF~ FRP GROUPED_DOAJ H13 M~E OK1 RPM RSF NPM EBS UCJ 7X8 5PM |
| ID | FETCH-LOGICAL-a505t-b5ce9e432b8c56fecf2f7c0eb54a92aaa627f616361c7d2d34cbb4a913f654ec3 |
| IEDL.DBID | DOA |
| ISSN | 2165-0497 |
| IngestDate | Wed Aug 27 01:25:45 EDT 2025 Thu Aug 21 18:36:42 EDT 2025 Fri Jul 11 05:27:59 EDT 2025 Mon May 22 18:20:19 EDT 2023 Thu Apr 03 07:13:22 EDT 2025 Tue Jul 01 00:42:48 EDT 2025 Thu Apr 24 22:50:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | microbiota side effect chemotherapy Ganoderma lucidum polysaccharide cachexia |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a505t-b5ce9e432b8c56fecf2f7c0eb54a92aaa627f616361c7d2d34cbb4a913f654ec3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Sung-Yu Wu and Chu-Chyn Ou contributed equally to this work. Author order was determined on the basis of seniority, data contribution, and coordinating role in this project. The authors declare no conflict of interest. |
| ORCID | 0000-0001-6855-9239 |
| OpenAccessLink | https://doaj.org/article/13a0e0c0235c422987a48fce97d5ce45 |
| PMID | 37212664 |
| PQID | 2817776073 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_13a0e0c0235c422987a48fce97d5ce45 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10269453 proquest_miscellaneous_2817776073 asm2_journals_10_1128_spectrum_03130_22 pubmed_primary_37212664 crossref_citationtrail_10_1128_spectrum_03130_22 crossref_primary_10_1128_spectrum_03130_22 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Jun-15 |
| PublicationDateYYYYMMDD | 2023-06-15 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-Jun-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Microbiol Spectr |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2023 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 Touchefeu, Y, Montassier, E, Nieman, K, Gastinne, T, Potel, G, Bruley Des Varannes, S, Le Vacon, F, de La Cochetière, M (B17) 2014; 40 Ubachs, J, Ziemons, J, Soons, Z, Aarnoutse, R, van Dijk, DPJ, Penders, J, van Helvoort, A, Smidt, ML, Kruitwagen, RFPM, Baade-Corpelijn, L, Olde Damink, SWM, Rensen, SS (B8) 2021; 12 Barreto, R, Waning, DL, Gao, H, Liu, Y, Zimmers, TA, Bonetto, A (B9) 2016; 7 Ou, C-C, Hsiao, Y-M, Hou, T-Y, Wu, M-F, Ko, J-L (B40) 2015; 19 Zhu, J, Xu, J, Jiang, LL, Huang, JQ, Yan, JY, Chen, YW, Yang, Q (B22) 2019; 35 Guo, C, Guo, D, Fang, L, Sang, T, Wu, J, Guo, C, Wang, Y, Wang, Y, Chen, C, Chen, J, Chen, R, Wang, X (B33) 2021; 267 Pötgens, SA, Thibaut, MM, Joudiou, N, Sboarina, M, Neyrinck, AM, Cani, PD, Claus, SP, Delzenne, NM, Bindels, LB (B36) 2021; 12 Luo, J, Zhang, C, Liu, R, Gao, L, Ou, S, Liu, L, Peng, X (B26) 2018; 47 Khan, I, Huang, G, Li, X-a, Liao, W, Leong, WK, Xia, W, Bian, X, Wu, J, Hsiao, WW (B25) 2019; 148 Bindels, LB, Beck, R, Schakman, O, Martin, JC, De Backer, F, Sohet, FM, Dewulf, EM, Pachikian, BD, Neyrinck, AM, Thissen, J-P, Verrax, J, Calderon, PB, Pot, B, Grangette, C, Cani, PD, Scott, KP, Delzenne, NM (B18) 2012; 7 Konishi, M, Ishida, J, von Haehling, S, Anker, SD, Springer, J (B5) 2016; 7 Pötgens, SA, Brossel, H, Sboarina, M, Catry, E, Cani, PD, Neyrinck, AM, Delzenne, NM, Bindels, LB (B37) 2018; 8 Darzian Rostami, A, Yazdian, F, Mirjani, R, Soleimani, M (B42) 2020; 36 Tisdale, MJ (B43) 2010; 142 Garcia, JM, Scherer, T, Chen, J-A, Guillory, B, Nassif, A, Papusha, V, Smiechowska, J, Asnicar, M, Buettner, C, Smith, RG (B15) 2013; 154 Chen, H, Xu, C, Zhang, F, Liu, Y, Guo, Y, Yao, Q (B19) 2020; 85 Shao, W, Xiao, C, Yong, T, Zhang, Y, Hu, H, Xie, T, Liu, R, Huang, L, Li, X, Xie, Y, Zhang, J, Chen, S, Cai, M, Chen, D, Liu, Y, Gao, X, Wu, Q (B35) 2022; 197 Fearon, K, Strasser, F, Anker, SD, Bosaeus, I, Bruera, E, Fainsinger, RL, Jatoi, A, Loprinzi, C, MacDonald, N, Mantovani, G, Davis, M, Muscaritoli, M, Ottery, F, Radbruch, L, Ravasco, P, Walsh, D, Wilcock, A, Kaasa, S, Baracos, VE (B2) 2011; 12 Ziemons, J, Smidt, ML, Damink, SO, Rensen, SS (B7) 2021; 35 Chang, C-J, Lin, C-S, Lu, C-C, Martel, J, Ko, Y-F, Ojcius, DM, Tseng, S-F, Wu, T-R, Chen, Y-YM, Young, JD, Lai, H-C (B29) 2015; 6 Onesti, JK, Guttridge, DC (B4) 2014; 2014 Fearon, KC, Glass, DJ, Guttridge, DC (B3) 2012; 16 Genton, L, Mareschal, J, Charretier, Y, Lazarevic, V, Bindels, LB, Schrenzel, J (B6) 2019; 9 Hatter, JA, Kouche, YM, Melchor, SJ, Ng, K, Bouley, DM, Boothroyd, JC, Ewald, SE (B45) 2018; 13 Qiu, W-L, Hsu, W-H, Tsao, S-M, Tseng, A-J, Lin, Z-H, Hua, W-J, Yeh, H, Lin, T-E, Chen, C-C, Chen, L-S, Lin, T-Y (B23) 2021; 13 Fanzani, A, Zanola, A, Rovetta, F, Rossi, S, Aleo, MF (B13) 2011; 250 Chen, JA, Splenser, A, Guillory, B, Luo, J, Mendiratta, M, Belinova, B, Halder, T, Zhang, G, Li, YP, Garcia, JM (B10) 2015; 6 Bindels, LB, Neyrinck, AM, Salazar, N, Taminiau, B, Druart, C, Muccioli, GG, François, E, Blecker, C, Richel, A, Daube, G, Mahillon, J, de los Reyes-Gavilán, CG, Cani, PD, Delzenne, NM (B38) 2015; 10 Tang, G, Du, Y, Guan, H, Jia, J, Zhu, N, Shi, Y, Rong, S, Yuan, W (B44) 2022; 179 Chiu, LY, Hsin, IL, Tsai, JN, Chen, CJ, Ou, CC, Wu, WJ, Sheu, GT, Ko, JL (B46) 2021; 236 Evans, WJ, Morley, JE, Argilés, J, Bales, C, Baracos, V, Guttridge, D, Jatoi, A, Kalantar-Zadeh, K, Lochs, H, Mantovani, G, Marks, D, Mitch, WE, Muscaritoli, M, Najand, A, Ponikowski, P, Rossi Fanelli, F, Schambelan, M, Schols, A, Schuster, M, Thomas, D, Wolfe, R, Anker, SD (B1) 2008; 27 Coletti, D (B11) 2018; 28 Sang, T, Guo, C, Guo, D, Wu, J, Wang, Y, Wang, Y, Chen, J, Chen, C, Wu, K, Na, K, Li, K, Fang, L, Guo, C, Wang, X (B30) 2021; 256 Lin, YL, Liang, YC, Lee, SS, Chiang, BL (B24) 2005; 78 Xie, J, Liu, Y, Chen, B, Zhang, G, Ou, S, Luo, J, Peng, X (B34) 2019; 63 Montassier, E, Gastinne, T, Vangay, P, Al-Ghalith, GA, Bruley Des Varannes, S, Massart, S, Moreau, P, Potel, G, de La Cochetière, MF, Batard, E, Knights, D (B16) 2015; 42 Georgoulias, V, Ardavanis, A, Agelidou, A, Agelidou, M, Chandrinos, V, Tsaroucha, E, Toumbis, M, Kouroussis, C, Syrigos, K, Polyzos, A, Samaras, N, Papakotoulas, P, Christofilakis, C, Ziras, N, Alegakis, A (B28) 2004; 22 Zhou, H, Sun, F, Li, H, Zhang, S, Liu, Z, Pei, J, Liang, C (B41) 2013; 35 Yang, Y, Zhang, H, Zuo, J, Gong, X, Yi, F, Zhu, W, Li, L (B20) 2019; 3 Koh, A, De Vadder, F, Kovatcheva-Datchary, P, Bäckhed, F (B21) 2016; 165 Pillai, TG, John, M, Thomas, GS (B39) 2011; 63 Le Bricon, T, Gugins, S, Cynober, L, Baracos, V (B14) 1995; 44 Tao, H, Tang, X, Jin, L, Zhao, Y, Luo, Y, Zhang, Z, Cai, L, Tao, F, Guo, W (B27) 2018; 505 Chen, M, Xiao, D, Liu, W, Song, Y, Zou, B, Li, L, Li, P, Cai, Y, Liu, D, Liao, Q, Xie, Z (B31) 2020; 155 Damrauer, JS, Stadler, ME, Acharyya, S, Baldwin, AS, Couch, ME, Guttridge, DC (B12) 2018; 28 Li, K, Zhuo, C, Teng, C, Yu, S, Wang, X, Hu, Y, Ren, G, Yu, M, Qu, J (B32) 2016; 93 |
| References_xml | – ident: e_1_3_3_34_2 doi: 10.1016/j.carbpol.2021.118231 – ident: e_1_3_3_37_2 doi: 10.1002/jcsm.12684 – ident: e_1_3_3_39_2 doi: 10.1371/journal.pone.0131009 – ident: e_1_3_3_4_2 doi: 10.1016/j.cmet.2012.06.011 – ident: e_1_3_3_16_2 doi: 10.1210/en.2013-1179 – ident: e_1_3_3_26_2 doi: 10.1016/j.phrs.2019.104448 – ident: e_1_3_3_43_2 doi: 10.1002/btpr.3027 – ident: e_1_3_3_10_2 doi: 10.18632/oncotarget.9779 – ident: e_1_3_3_11_2 doi: 10.1002/jcsm.12023 – ident: e_1_3_3_3_2 doi: 10.1016/S1470-2045(10)70218-7 – ident: e_1_3_3_41_2 doi: 10.1016/j.jff.2015.09.042 – ident: e_1_3_3_2_2 doi: 10.1016/j.clnu.2008.06.013 – ident: e_1_3_3_8_2 doi: 10.1016/j.beem.2021.101508 – ident: e_1_3_3_45_2 doi: 10.1111/bph.15693 – ident: e_1_3_3_15_2 doi: 10.1016/0026-0495(95)90040-3 – ident: e_1_3_3_38_2 doi: 10.1038/s41598-018-30569-5 – ident: e_1_3_3_44_2 doi: 10.1016/j.cell.2010.08.004 – ident: e_1_3_3_28_2 doi: 10.1016/j.bbrc.2018.09.105 – ident: e_1_3_3_5_2 doi: 10.1155/2014/168407 – ident: e_1_3_3_25_2 doi: 10.1189/jlb.0804481 – ident: e_1_3_3_6_2 doi: 10.1002/jcsm.12111 – ident: e_1_3_3_21_2 doi: 10.1186/s41702-019-0044-0 – ident: e_1_3_3_29_2 doi: 10.1200/JCO.2004.11.004 – ident: e_1_3_3_31_2 doi: 10.1016/j.carbpol.2020.117594 – ident: e_1_3_3_27_2 doi: 10.1016/j.jff.2018.05.041 – ident: e_1_3_3_35_2 doi: 10.29219/fnr.v63.1559 – ident: e_1_3_3_46_2 doi: 10.1371/journal.pone.0204895 – ident: e_1_3_3_13_2 doi: 10.4081/ejtm.2018.7590 – ident: e_1_3_3_23_2 doi: 10.1002/kjm2.12020 – ident: e_1_3_3_36_2 doi: 10.1016/j.ijbiomac.2021.12.034 – ident: e_1_3_3_33_2 doi: 10.1016/j.ijbiomac.2016.09.029 – ident: e_1_3_3_19_2 doi: 10.1371/journal.pone.0037971 – ident: e_1_3_3_30_2 doi: 10.1038/ncomms8489 – ident: e_1_3_3_14_2 doi: 10.1016/j.taap.2010.11.003 – ident: e_1_3_3_32_2 doi: 10.1016/j.ijbiomac.2019.11.047 – ident: e_1_3_3_42_2 doi: 10.3109/08923973.2013.791834 – ident: e_1_3_3_12_2 doi: 10.4081/ejtm.2018.7587 – ident: e_1_3_3_7_2 doi: 10.3389/fcimb.2019.00305 – ident: e_1_3_3_40_2 doi: 10.1016/j.etp.2009.11.003 – ident: e_1_3_3_17_2 doi: 10.1111/apt.13302 – ident: e_1_3_3_22_2 doi: 10.1016/j.cell.2016.05.041 – ident: e_1_3_3_9_2 doi: 10.1002/jcsm.12804 – ident: e_1_3_3_47_2 doi: 10.1002/jcp.29924 – ident: e_1_3_3_18_2 doi: 10.1111/apt.12878 – ident: e_1_3_3_20_2 doi: 10.1007/s00280-020-04060-w – ident: e_1_3_3_24_2 doi: 10.3390/polym13244353 – volume: 12 start-page: 456 year: 2021 end-page: 475 ident: B36 article-title: Multi-compartment metabolomics and metagenomics reveal major hepatic and intestinal disturbances in cancer cachectic mice publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12684 – volume: 6 start-page: 7489 year: 2015 ident: B29 article-title: Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota publication-title: Nat Commun doi: 10.1038/ncomms8489 – volume: 40 start-page: 409 year: 2014 end-page: 421 ident: B17 article-title: Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12878 – volume: 16 start-page: 153 year: 2012 end-page: 166 ident: B3 article-title: Cancer cachexia: mediators, signaling, and metabolic pathways publication-title: Cell Metab doi: 10.1016/j.cmet.2012.06.011 – volume: 142 start-page: 511 year: 2010 end-page: 512 ident: B43 article-title: Reversing cachexia publication-title: Cell doi: 10.1016/j.cell.2010.08.004 – volume: 6 start-page: 132 year: 2015 end-page: 143 ident: B10 article-title: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12023 – volume: 35 start-page: 426 year: 2013 end-page: 433 ident: B41 article-title: Effect of recombinant Ganoderma lucidum immunoregulatory protein on cyclophosphamide-induced leukopenia in mice publication-title: Immunopharmacol Immunotoxicol doi: 10.3109/08923973.2013.791834 – volume: 8 start-page: 12321 year: 2018 ident: B37 article-title: Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction publication-title: Sci Rep doi: 10.1038/s41598-018-30569-5 – volume: 2014 start-page: 168407 year: 2014 ident: B4 article-title: Inflammation based regulation of cancer cachexia publication-title: Biomed Res Int doi: 10.1155/2014/168407 – volume: 44 start-page: 1340 year: 1995 end-page: 1348 ident: B14 article-title: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats publication-title: Metabolism doi: 10.1016/0026-0495(95)90040-3 – volume: 93 start-page: 904 year: 2016 end-page: 912 ident: B32 article-title: Effects of Ganoderma lucidum polysaccharides on chronic pancreatitis and intestinal microbiota in mice publication-title: Int J Biol Macromol doi: 10.1016/j.ijbiomac.2016.09.029 – volume: 63 start-page: 1559 year: 2019 ident: B34 article-title: Ganoderma lucidum polysaccharide improves rat DSS-induced colitis by altering cecal microbiota and gene expression of colonic epithelial cells publication-title: Food Nutr Res doi: 10.29219/fnr.v63.1559 – volume: 28 start-page: 158 year: 2018 end-page: 166 ident: B12 article-title: Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia publication-title: Eur J Transl Myol doi: 10.4081/ejtm.2018.7590 – volume: 7 start-page: 107 year: 2016 end-page: 109 ident: B5 article-title: Nutrition in cachexia: from bench to bedside publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12111 – volume: 78 start-page: 533 year: 2005 end-page: 543 ident: B24 article-title: Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-κB and p38 mitogen-activated protein kinase pathways publication-title: J Leukoc Biol doi: 10.1189/jlb.0804481 – volume: 12 start-page: 2007 year: 2021 end-page: 2021 ident: B8 article-title: Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12804 – volume: 35 start-page: 222 year: 2019 end-page: 229 ident: B22 article-title: Improved antitumor activity of cisplatin combined with Ganoderma lucidum polysaccharides in U14 cervical carcinoma-bearing mice publication-title: Kaohsiung J Med Sci doi: 10.1002/kjm2.12020 – volume: 236 start-page: 1148 year: 2021 end-page: 1157 ident: B46 article-title: Combination treatment of Src inhibitor saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells publication-title: J Cell Physiol doi: 10.1002/jcp.29924 – volume: 9 start-page: 305 year: 2019 ident: B6 article-title: Targeting the gut microbiota to treat cachexia publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2019.00305 – volume: 36 year: 2020 ident: B42 article-title: Effects of different graphene-based nanomaterials as elicitors on growth and ganoderic acid production by Ganoderma lucidum publication-title: Biotechnol Prog doi: 10.1002/btpr.3027 – volume: 13 year: 2018 ident: B45 article-title: Toxoplasma gondii infection triggers chronic cachexia and sustained commensal dysbiosis in mice publication-title: PLoS One doi: 10.1371/journal.pone.0204895 – volume: 505 start-page: 372 year: 2018 end-page: 377 ident: B27 article-title: Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2018.09.105 – volume: 154 start-page: 3118 year: 2013 end-page: 3129 ident: B15 article-title: Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice publication-title: Endocrinology doi: 10.1210/en.2013-1179 – volume: 155 start-page: 890 year: 2020 end-page: 902 ident: B31 article-title: Intake of Ganoderma lucidum polysaccharides reverses the disturbed gut microbiota and metabolism in type 2 diabetic rats publication-title: Int J Biol Macromol doi: 10.1016/j.ijbiomac.2019.11.047 – volume: 63 start-page: 157 year: 2011 end-page: 160 ident: B39 article-title: Prevention of cisplatin induced nephrotoxicity by terpenes isolated from Ganoderma lucidum occurring in southern parts of India publication-title: Exp Toxicol Pathol doi: 10.1016/j.etp.2009.11.003 – volume: 42 start-page: 515 year: 2015 end-page: 528 ident: B16 article-title: Chemotherapy-driven dysbiosis in the intestinal microbiome publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13302 – volume: 19 start-page: 451 year: 2015 end-page: 463 ident: B40 article-title: Fungal immunomodulatory proteins alleviate docetaxel-induced adverse effects publication-title: J Funct Foods doi: 10.1016/j.jff.2015.09.042 – volume: 28 start-page: 153 year: 2018 end-page: 157 ident: B11 article-title: Chemotherapy-induced muscle wasting: an update publication-title: Eur J Transl Myol doi: 10.4081/ejtm.2018.7587 – volume: 47 start-page: 127 year: 2018 end-page: 135 ident: B26 article-title: Ganoderma lucidum polysaccharide alleviating colorectal cancer by alteration of special gut bacteria and regulation of gene expression of colonic epithelial cells publication-title: J Funct Foods doi: 10.1016/j.jff.2018.05.041 – volume: 12 start-page: 489 year: 2011 end-page: 495 ident: B2 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70218-7 – volume: 197 start-page: 23 year: 2022 end-page: 38 ident: B35 article-title: A polysaccharide isolated from Ganoderma lucidum ameliorates hyperglycemia through modulating gut microbiota in type 2 diabetic mice publication-title: Int J Biol Macromol doi: 10.1016/j.ijbiomac.2021.12.034 – volume: 179 start-page: 159 year: 2022 end-page: 178 ident: B44 article-title: Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2-mediated PI3K/Akt/mTOR signals publication-title: Br J Pharmacol doi: 10.1111/bph.15693 – volume: 10 year: 2015 ident: B38 article-title: Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia in mice publication-title: PLoS One doi: 10.1371/journal.pone.0131009 – volume: 250 start-page: 312 year: 2011 end-page: 321 ident: B13 article-title: Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2010.11.003 – volume: 7 year: 2012 ident: B18 article-title: Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model publication-title: PLoS One doi: 10.1371/journal.pone.0037971 – volume: 3 start-page: 6 year: 2019 ident: B20 article-title: Advances in research on the active constituents and physiological effects of Ganoderma lucidum publication-title: Biomed Dermatol doi: 10.1186/s41702-019-0044-0 – volume: 22 start-page: 2602 year: 2004 end-page: 2609 ident: B28 article-title: Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non–small-cell lung cancer: a randomized, multicenter phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2004.11.004 – volume: 267 start-page: 118231 year: 2021 ident: B33 article-title: Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon publication-title: Carbohydr Polym doi: 10.1016/j.carbpol.2021.118231 – volume: 165 start-page: 1332 year: 2016 end-page: 1345 ident: B21 article-title: From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites publication-title: Cell doi: 10.1016/j.cell.2016.05.041 – volume: 256 start-page: 117594 year: 2021 ident: B30 article-title: Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation publication-title: Carbohydr Polym doi: 10.1016/j.carbpol.2020.117594 – volume: 27 start-page: 793 year: 2008 end-page: 799 ident: B1 article-title: Cachexia: a new definition publication-title: Clin Nutr doi: 10.1016/j.clnu.2008.06.013 – volume: 35 start-page: 101508 year: 2021 ident: B7 article-title: Gut microbiota and metabolic aspects of cancer cachexia publication-title: Best Pract Res Clin Endocrinol Metab doi: 10.1016/j.beem.2021.101508 – volume: 7 start-page: 43442 year: 2016 end-page: 43460 ident: B9 article-title: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs publication-title: Oncotarget doi: 10.18632/oncotarget.9779 – volume: 85 start-page: 1049 year: 2020 end-page: 1062 ident: B19 article-title: The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-020-04060-w – volume: 13 start-page: 4353 year: 2021 ident: B23 article-title: Wsg, a glucose-rich polysaccharide from Ganoderma lucidum, combined with cisplatin potentiates inhibition of lung cancer in vitro and in vivo publication-title: Polymers doi: 10.3390/polym13244353 – volume: 148 start-page: 104448 year: 2019 ident: B25 article-title: Mushroom polysaccharides and jiaogulan saponins exert cancer preventive effects by shaping the gut microbiota and microenvironment in ApcMin/+ mice publication-title: Pharmacol Res doi: 10.1016/j.phrs.2019.104448 |
| SSID | ssj0001105252 |
| Score | 2.3081162 |
| Snippet | Cachexia is a multifactorial syndrome driven by metabolic dysregulation, anorexia, systemic inflammation, and insulin resistance. Approximately 80% of patients... Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia and... ABSTRACT Cachexia is a lethal muscle-wasting syndrome associated with cancer and chemotherapy use. Mounting evidence suggests a correlation between cachexia... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0313022 |
| SubjectTerms | cachexia chemotherapy Ganoderma lucidum polysaccharide Human Microbiome microbiota Research Article side effect |
| SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA7LLoIv4t16I4IgCF3b3Ps4Dq6LsuqDA_sW0jTBgV6G7RTsi7_dk0w7OrIsvuZC0nNyTr40Od9B6HWgMAdDECn1NkuZNyQtOS3SArYfplwunY0PZL-I8xX7dMkvj5CYY2EmCfanpm_iRf7esol6F4MPr4bmNBAOZikB13vCScHAIE8Wi9XXz3_-ruQhPxuZrjGv7Qs-GMYgB_tRpO2_Dmv--2Tyrz3o7C66M4FHvNhp-x46cu19dGuXTnJ8gH596-qxNzZEUq0rhzuPP5o2JDtrDK4Hu66GBi8aV4ewfICYeBnYnEOQFL4Yu5CbeMQhlYd1FS5HDNAQg7uAo3PUHl6u-014OdfiTT30GLYntzU_XY2h5AL8zUO0OvvwfXmeTvkVUgO4ZwtKsa5wjJJSWS68s554aTNXcmYKYowRRHoBgE3kVlakosyWJVTl1AvOnKWP0HHbte4JwgAcVS4qQOoKznssg_6-kEZ4RnJPqUvQmyBsPatXx7MHUXpWi45q0YQkKJv1oe1EUx6yZdQ3dXm777LZcXTc1Ph9UPK-YaDXjgWw2PRkrTqnJnOZDVxAlhH4KGmY8iAtWYHMGE_Qq3mJaDDHcMdiWtcNvSYql1IKcJwJerxbMvuhKJy2AQ-xBKmDxXQwl8Oadv0jUn4DDBQF4_Tpf8vxGbpNYP7hVVvOn6NjqHQvAD9ty5eTsfwGNs0bEA priority: 102 providerName: American Society for Microbiology |
| Title | Polysaccharide of Ganoderma lucidum Ameliorates Cachectic Myopathy Induced by the Combination Cisplatin plus Docetaxel in Mice |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37212664 https://journals.asm.org/doi/10.1128/spectrum.03130-22 https://www.proquest.com/docview/2817776073 https://pubmed.ncbi.nlm.nih.gov/PMC10269453 https://doaj.org/article/13a0e0c0235c422987a48fce97d5ce45 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9QwFA4yIniR9XfddYkgCELdNknT9jgOrouy6sGBvYU0TXCgPwY7he1l__Z9L-0MMyLrxWvT0JD3kve95uX7CHmLFOawEGTInYlC4TQLi4TnYQ7hR2Q2Tq3xBbLf5MVSfLlKrvakvrAmbKQHHifuLOY6spFBWhYjGIMUWYvMGZunZWKs8OylEPP2kin_dyVGfTY2HWPCHnzmLy7-7usPSFYYhSiWO9NdzQ7ikaft_xvW_LNkci8GnR-RRxN4pPNx0I_JPds8IQ9GOcnhKbn50VZDpw3epFqVlraOftYNip3Vmla9WZV9Tee1rfBaPkBMukA2Z7wkRS-HFrWJB4pSHsaWtBgoQEMK2wWkzt56dLHq1lg519B11XcUwpPd6GtbUXhyCfvNM7I8__RzcRFO-gqhBtyzAaPANFrBWZGZRDprHHOpiWyRCJ0zrbVkqZMA2GRs0pKVXJiigKaYO5kIa_hzMmvaxr4kFIBjFssSkHoG-Z6IoL_LUy2dYLHj3AbkHU62mhZIp3zuwTK1NYvyZlGMBSTa2kOZiaYc1TKqu7q833VZjxwdd738EY28exHptf0DcDo1OZ36l9MF5M3WRRQsRzxj0Y1t-06xLE7TVMLGGZAXo8vsPsUh2wY8JAKSHTjTwVgOW5rVL0_5DTBQ5iLhr_7H6I_JQwaNWPAWJydkBvNjXwO02hSn5P58vvz-9dSvpls_TyTn |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA9yh-iL-G39jCAIQs82SZP2cV08V-_29OEW7i2kacKt9GOxW7Av_u3OdLurK8fha5PQJpOZ_KaZ-Q0hb5DCHBRBhtzbKBTesDBPeBZmcPyI1MXK2SFA9kzOFuLLRXIxRlViLsx3rMtbtkemrYZ7fFRs_BE91iNM3w8JiD-66ghJB6OQgfk9xLtDcLwOJ5PF15M_f1hirNHGxqvMK8eCHYYXsb0zaaDuvwpv_hs2-dc5dHyX3BkBJJ1sJH6P3HD1fXJzU1Kyf0B-fWvKvjUWs6mWhaONp59MjQXPKkPLzi6LrqKTypWYmg8wk06R0RkTpei8b7A-cU-xnId1Bc17CvCQgskA93mQIJ0u2xVGz9V0VXYthSPKrc1PV1J4Mgeb85Asjj-eT2fhWGMhNIB91iAY6zInOMtTm0jvrGde2cjliTAZM8ZIprwE0CZjqwpWcGHzHJpi7mUinOWPyEHd1O4JoQAe01gWgNZT8PlEBON9poz0gsWecxeQt7jYelSSVg_-B0v1Vix6EItmLCDRVh7ajlTlWDGjvG7Iu92Q1Yan47rOH1DIu45IsT08gB2nR43VMTeRiyzyAVnBYFLKiNTDaqkC1kwkAXm93SIaVBLvWUztmq7VLI2VUhKMZ0Aeb7bM7lUcPG7ARCIg6d5m2vuW_ZZ6eTnQfgMUlJlI-NP_XsdX5NbsfH6qTz-fnTwjtxnMBaPc4uQ5OYCO7gXgqXX-clSc3_NCH3M |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA-yh-KL-G3PrwiCIPRskzRpH9fV9fS88x5cuLeQpgku9GOxW7i--Lc70-2urhyHr01C2pnM5Jdm5jeEvEYKczAEGXJvo1B4w8I84VmYwfYjUhcrZ4cA2TN5vBBfLpKLMaoSc2FGCbZHpq2Gi3y07FXhx3qE6bshAfFnVx0h6WAUMnC_B8Nl1YQcTKeLbyd__rDEWKONjVeZV44FPwzzsL09aaDuvwpv_hs2-dc-NL9L7owAkk43Gr9Hbrj6Prm5KSnZPyC_zpuyb43FbKpl4Wjj6SdTY8GzytCys8uiq-i0ciWm5gPMpDNkdMZEKXraN1ifuKdYzsO6guY9BXhIwWXA8XnQIJ0t2xVGz9V0VXYthS3Krc2lKyk8OQWf85As5h-_z47DscZCaAD7rEEx1mVOcJanNpHeWc-8spHLE2EyZoyRTHkJoE3GVhWs4MLmOTTF3MtEOMsfkUnd1O4JoQAe01gWgNZTOPOJCMb7TBnpBYs95y4gb1DYeqtiPZw_WKq3atGDWjRjAYm2-tB2pCrHihnldUPe7oasNjwd13V-j0redUSK7eEBLDg9WqyOuYlcZJEPyAoGH6WMSD1ISxUgM5EE5NV2iWgwSbxnMbVrulazNFZKSXCeAXm8WTK7qTicuAETiYCke4tp7132W-rlj4H2G6CgzETCD_9bji_JrfMPc_3189nJU3KbwadgkFucPCMT6OeeA5xa5y9Gu_kNtVsfDw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polysaccharide+of+Ganoderma+lucidum+Ameliorates+Cachectic+Myopathy+Induced+by+the+Combination+Cisplatin+plus+Docetaxel+in+Mice&rft.jtitle=Microbiology+spectrum&rft.au=Sung-Yu+Wu&rft.au=Chu-Chyn+Ou&rft.au=Meng-Lin+Lee&rft.au=I-Lun+Hsin&rft.date=2023-06-15&rft.pub=American+Society+for+Microbiology&rft.eissn=2165-0497&rft.volume=11&rft.issue=3&rft_id=info:doi/10.1128%2Fspectrum.03130-22&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_13a0e0c0235c422987a48fce97d5ce45 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |